NEW YORK, April 25, 2017 /PRNewswire/ --
On Monday, the NASDAQ Composite ended the day at 5,983.82, up 1.24%; the Dow Jones Industrial Average edged 1.05% higher, to finish at 20,763.89; and the S&P 500 closed at 2,374.15, marginally gaining 1.08%. Gains were broad based as nine out of nine sectors finished the trading session in green. Stock-Callers.com has initiated research reports on the following Biotechnology stocks: Novan Inc. (NASDAQ: NOVN), Stemline Therapeutics Inc. (NASDAQ: STML), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI). Learn more about these stocks by downloading their comprehensive and free reports at:
On Monday, shares in Durham, North Carolina headquartered Novan Inc. ended the session 2.40% lower at $5.28 with a total volume of 98,915 shares traded. The stock is trading 10.83% below its 50-day moving average and 66.91% below its 200-day moving average. Moreover, shares of the Company, which focuses on the development and commercialization of nitric oxide-based therapies in dermatology, have a Relative Strength Index (RSI) of 43.17. NOVN complete research report is just a click away and free at:
On Monday, shares in New York-based Stemline Therapeutics Inc. recorded a trading volume of 91,097 shares. The stock ended the day 1.16% higher at $8.75. Stemline Therapeutics' stock has gained 2.94% in the last one month and 57.09% in the previous one year. The Company's shares are trading above its 50-day moving average by 6.85%. Furthermore, shares of Stemline Therapeutics, which focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the US, have an RSI of 56.57. The complimentary report on STML can be downloaded at:
Raleigh, North Carolina headquartered BioDelivery Sciences International Inc.'s stock finished Monday's session 6.25% higher at $1.70 with a total volume of 506,027 shares traded. The Company's shares are trading below its 50-day and 200-day moving averages by 10.22% and 20.48%, respectively. Shares of BioDelivery Sciences International, which engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction, have an RSI of 44.06. Sign up for your complimentary research report on BDSI at:
Bothell, Washington headquartered OncoGenex Pharmaceuticals Inc.'s stock fell 4.18%, to close the day at $0.35. The stock recorded a trading volume of 263,893 shares, which was above its three months average volume of 187,680 shares. The Company's shares are trading 28.41% and 36.25% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which develops and commercializes therapies that address treatment resistance in cancer patients, have an RSI of 28.13. Get free access to your research report on OGXI at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA